Abstract
Glioblastoma multiforme (GBM), the most common and lethal brain cancer,
prognosis remains bleak with a median survival of about 15 months despite
maximal surgical resection, radiotherapy, and temozolomide treatment. The
difficulty associated with safely and effectively delivering therapeutics across
the blood brain barrier (BBB) is a major challenge towards GBM treatment.
Ongoing research and clinical trials, including attempts to deliver therapeutics
within stem cells present possible solutions. The relationships between brain
cancer pathology, stem cell properties, therapeutic advantages and disadvan-
tages of various stem cell types, drug delivery methods, cancer stem cells,
gene therapy, anti-cancer vaccines, chimeric antigen receptor therapies, and
combination therapies are discussed.
References
Stem Cell Therapy for Brain Tumors 97
cytotoxic mesenchymal stromal cells optimized by bioluminescence
imaging of tumor and therapeutic cell response. PloS One 7 (4):e35148.
Altanerova, V., M. Cihova, M. Babic, B. Rychly, K. Ondicova,
B. Mravec, and C. Altaner. 2012. Human adipose tissue-derived
mesenchymal stem cells expressing yeast cytosinedeaminase::uracil
phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int. J.
Cancer 130 (10): 2455–2463.
Roger, M., A. Clavreul, N. Trinh Huynh, C. Passirani, P. Schiller, A.
Vessi`eres, C. Montero-Meneia, and P. Menei. 2011. Ferrociphenol lipid
nanocapsule delivery by mesenchymal stromal cells in brain tumor
therapy. Int. J. Pharm. 423 (1): 63–68.
Kim, S. M., J. S. Woo, C. H. Jeong, C. H. Ryu, J. D. Jang, and S.
S. Jeun. 2014. Potential application of temozolomide in mesenchymal
stem cell-based trail gene therapy against malignant glioma. Stem Cells
Transl. Med. 3 (2): 172–182.
Snyder, E. Y., X. O. Breakefield, K. S. Aboody, U. Herrlinger, and W.
P. Lynch, inventor The Children’s MedicalCenter Corporation Boston,
MA, USA; The General Hospital Corporation, Charlestown, MA, USA;
Northeastern Ohio Universities College of Medicine, Rootstown, OH,
USA assignee. US Patent # 7186409. Neural stem cells and use
thereof for brain tumor therapy. United States 2007.
Ahmed, A. U., B. Thaci, A. L. Tobias, B. Auffinger, L. Zhang, Y. Cheng,
C. K. Kim, C. Yunis, Y. Han, N. G. Alexiades, X. Fan, K. S. Aboody,
and M. S. Lesniak. 2012. A preclinical evaluation of neural stem cell-
based cell carrier for targeted antiglioma oncolytic virotherapy. JNCI
(13): 968–977.
Cheng, Y., R. Morshed, S. H. Cheng, A. Tobias, B. Auffinger, D. A.
Wainwright, L. Zhang, C. Yunis, Y. Han, C. T. Chen, L. W. Lo, K.
S. Aboody, A. U. Ahmed, and M. S. Lesniak. 2013. Nanoparticle-
programmed self-destructive neural stem cells for glioblastoma target-
ing and therapy. Small 9 (24): 4123–4129.
Larsen, J. M., D. R. Martin., and M. E. Byrne. 2014. Recent advances
in delivery through the blood–brain barrier. Curr. Top. Med. Chem. 14
(9): 1148–1160.
Brem, H., M. G. Ewend, S. Piantadosi, J. Greenhoot, P. C. Burger, and
M. Sisti. 1995. The safety of interstitial chemotherapy with BCNU-
loaded polymer followed by radiation therapy in the treatment of newly
diagnosed malignant gliomas: phase I trial. J. Neurooncol. 26: 111–123.
A. Aleynik and P. Rameshwar
Hart, M. G., R. Grant, R. Garside, G. Rogers, M. Somerville, and K.
Stein. 2011. Chemotherapy wafers for high grade glioma. Cochrane
Database Syst. Rev. 3. doi:10.1002/14651858.CD007294.pub2.
Chowdhary, S. A., T. Ryken, and H. B. Newton. 2015. Survival out-
comes and safety of carmustine wafers in the treatment of high-grade
gliomas: a meta-analysis. J. Neurooncol. 122 (2): 367–382.
Salahuddin, T. S., B. B. Johansson, H. Kalimo, and Y. Olsson. 1988.
Structural changes in the rat brain after carotid infusions of hyperos-
molar solutions: a light microscopic and immunohistochemical study.
Neuropathol. Appl. Neurobiol. 77: 5–13.
Burgess, A., and K. Hynynen. 2013. Noninvasive and targeted drug
delivery to the brain using focused ultrasound ACS Chem. Neurosci. 4
(4): 519–526.
Egleton, R. D., and T. P. Davis. 2005. Development of neuropeptide
drugs that cross the blood–brain barrier. Neurotherapeutics 2 (1):
–53.
Ramalho-Santos, M., S. Yoon, Y. Matsuzaki, R. C. Mulligan, and D. A.
Melton. 2002. “Stemness”: transcriptional profiling of embryonic and
adult stem cells. Science 298 (5593): 597–600.
Sun, J., A. Ramos, B. Chapman, J. B. Johnnidis, L. Le, Y. J. Ho, A.
Klein, O. Hofmann, and F. D. Camargo. 2014. Clonal dynamics of
native haematopoiesis. Nature 514 (7522): 322–327.
Ning, J., and H. Wakimoto. 2014. Oncolytic herpes simplex virus-
based strategies: toward a breakthrough in glioblastoma therapy. Front.
Microbiol. 5 (303): 1–13.
Kaufmann, J. K., and E. A. Chiocca. 2014. Glioma virus therapies
between bench and bedside. Neuro-Oncology 16 (3): 334–351.
Kaufmann, J. K., and E.A. 2014. Chiocca. Glioma virus therapies
between bench and bedside. Neuro-Oncology 16: 334–351.
Russell, S. J., K. W. Peng, and J. C. Bell. 2014. Oncolytic virotherapy.
Nat. Biotechnol. 30: 1–29.
Wollmann, G., K. Ozduman, and A. N. van den Pol. 2012. Oncolytic
virus therapy of glioblastoma multiforme – concepts and candidates.
Cancer J. 18 (1): 69–81.
Rubsam, L. Z., P. D. Boucher, P. J. Murphy, M. KuKuruga, and
D. S. Shewach. 1999. Cytotoxicity and accumulation of ganciclovir
triphosphate in bystander cells cocultured with herpes simplex virus
type 1 thymidine kinase-expressing human glioblastoma cells. Cancer
Res. 59: 669–675.
Stem Cell Therapy for Brain Tumors 99
Beck, C., S. Cayeux, S. D. Lupton, B. Dörken, and T. Blankenstein.
The thymidine kinase/ganciclovir-mediated “suicide” effect is
variable in different tumor cells. Hum. Gene Ther. 6: 1525–1530.
Colombo, F., L. Barzon, E. Franchin, M. Pacenti, V. Pinna, D. Danieli,
M. Zanusso, and G. Palù. 2005. Combined HSV-TK/IL-2 gene therapy
in patients with recurrent glioblastoma multiforme: biological and
clinical results. Cancer Gene Ther. 12: 835–848.
Perry, J. R. 2012. Thromboembolic disease in patients with high-grade
glioma. Neuro-Oncology 14 (Suppl. iv): iv73–iv80.
De Cicco, M. 2004. The prothrombotic state in cancer: pathogenic
mechanisms. Crit. Rev. Oncol. Hematol. 50 (3): 187–196.
McKie, E. A., A. R. MacLean, A.D. Lewis, G. Cruickshank, R. Ram-
pling, S.C. Barnett, P.G. Kennedy, S.M. Brown. 1996. Selective in vitro
replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants
in primary human CNS tumours—evaluation of a potentially effective
clinical therapy. Br J Cancer 74 (5): 745–752.
Mineta, T., S. D. Rabkin, T. Yazaki, W. D. Hunter, R. L. Martuza. 1995.
Attentuated multi-mutated herpes simplex virus-1 for the treatment of
malignant gliomas. Nat. Med. 1 (9): 938–943.
Freeman, A. I., Z. Zakay-Rones, J. M. Gomori, E. Linetsky, L. Rasooly,
E. Greenbaum, S. Rozenman-Yair, A. Panet, E. Libson, C.S. Irving, E.
Galun, and T. Seigal. 2006. Phase I/II trial of intravenous NDV-HUJ
oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13:
–228.
Rainov, N.G. 2000. A Phase III Clinical evaluation of herpes sim-
plex virus type 1 thymidine kinase and ganciclovir gene therapy as
an adjuvant to surgical resection and radiation in adults with previ-
ously untreated glioblastoma multiforme. Hum. Gene Ther. 11 (17):
–2401.
Yla-Herttuala, M. W. S., J. Martin, P. Warnke, P.Menei, D. Eckland, J.
Kinley, R. Kay, and Z. Ram. 2013. Adenovirus-mediated gene therapy
with sitimagene ceradenovec followed by intravenous ganciclovir for
patients with operable high-grade gliomas (ASPECT): a randomised,
open-label, phase 3 trial. Lancet Oncol. 14 (9): 822–833.
Stupp, R., W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher,
M.J.B. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn,
J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D.
Lacombe, J. Gregory Cairncross, E. Eisenhauer, and R. O. Mirimanoff.
A. Aleynik and P. Rameshwar
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Eng. J. Med. 352: 987–996.
Barnett, S. C., L. Robertson, D. Graham, D. Allan, and R. Rampling.
Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells trans-
formed with c-myc and H-ras form high-grade glioma after stereotactic
injection into the rat brain. Carcinogenesis 19 (9): 1529–1537.
O’Neill, D. W., S. Adams, and N. Bhardwaj. 2004. Manipulating
dendritic cell biology for the active immunotherapy of cancer. Blood
(8): 2235–2246.
Ahmed, M. S., and Y. S. Bae. 2014. Dendritic cell-based therapeutic
cancer vaccines: past, present, and future. Clin. Exp. Vaccine 3 (2):
–116.
Schreiber R. D., L. J. Old, and M. J. Smyth. 2011. Cancer Immunoedit-
ing: Integrating immunity’s roles in cancer suppression and promotion.
Science 331 (6024): 1565–1570.
Fonteneau, J. F., M. Gilliet, M. Larsson, I. Dasilva, C. Munz, Y. J. Liu,
and N. Bhardwaj. 2003.Activation of influenza virus-specific CD4+ and
CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive
immunity. Blood 101 (9): 3520–3526.
Salio, M., M. Cella, W. Vermi, F. Facchetti, M. J. Palmowski, C. L.
Smith, D. Shepherd, M. Colonna, and V. Cerundulo. 2003. Plasmacytoid
dendritic cells prime IFN-gamma-secreting melanoma-specific CD8
lymphocytes and are found in primary melanoma lesions. Eur. J.
Immunol. 33: 1052–1062.
Eshhar, Z., T. Waks, G. Cross, and D. G. Schindler. 1993. Specific
activation and targeting of cytotoxiclymphocytes through chimeric
single chains consisting of antibody-binding domains and the y or
C subunits of the immunoglobulinand T-cell receptors. PNAS 90:
–724.
Miao, H., B. D. Choi, C. M. Suryadevara, L. Sanchez-Perez, S. Yang,
G. De Leon, E. J. Sayor, R. McLendon, J. E. Herndon II, P. Healy,
G. E. Archer, D. D. Binger, L. A. Johnson, and J. H. Sampson. 2014.
EGFRvIII-specific chimeric antigen receptor T cells migrate to and
kill tumor deposits infiltrating the brain parenchyma in an invasive
xenograft model of glioblastoma. PLos One 9 (4): 1–9.
Lee, D.W., D. M. Barrett, C. Mackall, R. Orentas, and S. A. Grupp.
The future is now: chimeric antigen receptors as new targeted
therapies for childhood cancer. CCR Focus 18 (10): 2780–2790.
Stem Cell Therapy for Brain Tumors 101
Imai, C., K. Mihara, M. Andreansky, I. C. Nicholson, C. H. Pui, T. L.
Geiger, and D. Campana. 2004. Chimeric receptors with 4-1BB signal-
ing capacity provoke potent cytotoxicity against acute lymphoblastic
leukemia. Leukemia 18: 676–684.
Carpentino, C., M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal,
M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S.
M. Albelda, R. G. Carroll, J. L. Riley, I. Pastan, and C. H. June.
Control of large, established tumor xenografts with genetically
retargeted human T cells containing CD28 and CD137 domains. PNAS
(9): 3360–3365.
Zhao, Y., Q. J. Wang, S. Yang, J. N. Kochenderfer, Z. Zheng, X. Zhong,
M. Sadelain, Z. Eshhar, S. A. Rosenberg, and R. A. Morgan. 2009.
A herceptin-based chimeric antigen receptor with modified signaling
domains leads to enhanced survival of transduced T lymphocytes and
antitumor activity. J. Immunol. 183 (9): 5563–5574.
Morgan, R. A. 2013. Risky business: target choice in adoptive cell
therapy. Blood 122 (20): 3392–3394.
Brentjens, R., R. Yeh, Y. Bernal, I. Riviere, and M. Sadelain. 2010.
Treatment of chronic lymphocytic leukemia with genetically targeted
autologous T cells: case report of an unforeseen adverse event in a phase
I clinical trial. Mol. Ther. 18 (4): 666–668.
Kochenderfer, J. N., M. E. Dudley, S. A. Feldman, W. H. Wilson, D.
E. Spaner, I. Maric, M. Stetler-Stevenson, G. Q. Phan, M. S. Hughes,
R. M. Sherry, J. C. Yang, U. S. Kammula, L. Devillier, R. Carpenter,
D. A. Nathan, R. A. Morgan, C. Laurencot, and S. A. Rosenberg. 2012.
B-cell depletion and remissions of malignancy along with cytokine-
associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-
receptor-transduced T cells. Blood 119 (12): 2709–2720.
Grupp, S. A., M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R.
Rheingold, D. T. Teachey, A. Chew, B. Hauck, J. Fraser Wright, M. C.
Milone, B. L. Levine, and C. H. June. 2013. chimeric antigen receptor-
modified t cells for acute lymphoid leukemia. N Engl. J. Med. 368 (16):
–1518.
Le Huu, D., T. Matsushita, G. Jin, Y. Hamaguchi, M. Hasegawa, K.
Takehara, and M. Fujimoto. 2012. IL-6 blockade attenuates the devel-
opment of murine sclerodermatous chronic graft-versus-host disease.
J. Invest. Dermatol. 132: 2752–2761.
Pule, M. A., B. Savoldo, G. D. Myers, C. Rossig, H. V. Russell, G. Dotti,
M. H. Huls, E. Liu, A. P. Gee, Z. Mei, E. Yvon, H. L. Weiss, H. Liu,
A. Aleynik and P. Rameshwar
C. M. Rooney, H. E. Heslop, and M. K. Brenner. 2008. Virus-specific
T cells engineered to coexpress tumor-specific receptors: persistence
and antitumor activity in individuals with neuroblastoma. Nat. Med. 14
(11): 1264–1270.
Hatiboglu, M. A., J. Wei, A. S. G. Wu, and A. B. Heimberger. 2010.
Immune therapeutic targeting of glioma cancer stem cells. Target Oncol.
(3): 217–227.
Barkholt, L., E. Flory, V. Jekerle, S. Lucas-Samuel, P. Ahnert, L. Bisset,
D. Büscher, W. Fibbe, A. Foussat, M. Kwa, O. Lantz, R. Maˇciulaitis,
T. Palomäki, C. K. Schneider, L. Sensebé, G. Tachdjian, K. Tarte, L.
Tosca, and P. Salmikangas. 2013. Risk of tumorigenicity in mesenchy-
mal stromal cell-based therapies–bridging scientific observations and
regulatory viewpoints. Cytotherapy 15 (7): 753–759.
Harsh, G. R., T. S. Deisboeck, D. N. Loius, J. Hilton, M. Colvin, J. S.
Silver, N. H. Qureshi, J. Kracher, D. Finkelstein, E. A. Chiocca, and
F. H. Hochberg. 2000. Thymidine kinase activation of ganciclovir in
recurrent malignant gliomas: a gene-marking and neuropathological
study. J. Neurosurg. 92 (5): 804–811.
Smith, A.G. 2001. Embryo-derived stem cells: of mice and men. Annu.
Rev. Cell Dev. Biol. 17: 435–462.
Le Blanc, K., and M. F. Pittenger. 2005. Mesenchymal stem cells:
progress toward promise. Cytotherapy 7 (1): 36–45.
Tolar, J., A. J. Nauta, M. J. Osborn, A. P. Mortari, R. T. McElmurry, S.
Bell, L. Xia, N. Zhou, M. Riddle, T. M. Schroeder, J. J. Westendorf,
R. S. McIvor, P. C. W. Hogendoorn, K. Szuhai, L. Oseth, B. Hirsch, S.
R. Yant, M. A. Kay, A. Peister, D. J. Prockop, W. E. Fibbe, and B. R.
Blazar. 2007. Sarcoma derived from cultured mesenchymal stem cells.
Stem Cells 25: 371–379.
Atsma D. E., W. E. Fibbe, and T. J. Rabelink. 2007. Opportunities
and challenges for mesenchymal stem cell-mediated heart repair. Curr.
Opin. Lipidol. 18 (6): 645–649.
Solchaga, L. A., K. J. Penick, and J. F. Welter. 2011. Chondrogenic
differentiation of bone marrow-derived mesenchymal stem cells: Tips
and Tricks. Methods Mol. Biol. 698: 253–278.
Wei X., X. Yang, Z. P. Han, F. F. Qu, L. Shao, and Y. F. Shi. 2013.
Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol.
Sinica 34 (6): 747–754.
Ryan, J. M., F. P. Barry, J. M. Murphy, and B. P. Mahon. 2005.
Mesenchymal stem cells avoid allogeneic rejection. J. Inflam. 2: 8.
Stem Cell Therapy for Brain Tumors 103
Medvedev, S. P., A. I. Shevchenk, and S. M. Zakian. 2010. Induced
pluripotent stem cells: problems and advantages when applying them
in regenerative medicine. ACTA NAT. 2 (5): 18–28.
Yamanaka, S. 2009. A FRESH Look at iPS cells. Cell 137 (1): 13–17.
Chan, T. M., J. Y. R. Chen, L. I. Ho, H. P. Lin, K. W. Hsueh, D. D. Liu,
Y. H. Chen, A. C. Hsieh, N. M. Tsai, D. Y. Hueng, S. T. Tsai, P. W. Chou,
S. Z. Lin, and H. J. Harn. 2014. ADSC Therapy in neurodegenerative
disorders. Cell Transplant. 23 (4–5): 549–557.
Desplats P., H. J. Lee, E. J. Bae, C. Patrick, E. Rockenstein, L. Crews,
B. Spencer, E. Masliah, and S. J. Lee. 2009. Inclusion formation and
neuronal cell death through neuron-to-neuron transmission of alpha-
synuclein. PNAS 106 (31): 13010–13015.
Sanberg, P. R., D. J. Eve, A. E. Willing, S. Garbuzova-Davis, J. Tan, C.
D. Sanberg, J. G. Allickson, E. L. Cruz, and C. V. Borlongan. 2011.
The treatment of neurodegenerative disorders using umbilical cord
blood and menstrual blood-derived stem cells. Cell Transplant. 20 (10):
–94.
Spinelli V., P. V. Guillot, and P. De Coppi. 2013. Induced pluripotent
stem (iPS) cells from human fetal stem cells (hFSCs). Organogenesis
(2): 101–110.
Broxmeyer, H. E. 2010. Umbilical cord transplantation: Epilogue.
Semin. Hematol. 47 (1): 97–103.
Altaner, C., V. Altanerova, M. Cihova, K. Ondicova, B. Rychly, L.
Baciak, and B. Mravec. 2014. Complete regression of glioblastoma
by mesenchymal stem cells mediated prodrug gene therapy simulating
clinical therapeutic scenario. International J. Cancer 134 (6): 1458–
Egleton, R. D., and T. P. Davis. 2005. Development of neuropeptide
drugs that cross the blood–brain barrier. NeuroRx 2 (1): 44–53.
Qin, J., X. Yang, J. Mi, J. Wang, J. Hou, T. Shen, Y. Li, B. Wang,
X. Li, and W. Zhu. 2014. Enhanced antidepressant-like effects of the
macromolecule trefoil factor 3 by loading into negatively charged
liposomes. Int. J. Nanomed. 9: 5247–5257.
Wang, X., P. Liu, W. Yang, L. Li, P. Li, Z. Liu, Z. Zhuo, and Y.
Gao. Microbubbles coupled to methotrexate-loaded liposomes for
ultrasound-mediated delivery of methotrexate across the blood–brain
barrier. Int. J. Med.; 9: 4899–4909.
Steiniger, S. C., J. Kreuter, A. S. Khalansky, I. N. Skidan, A. I.
Bobruskin, Z. S. Smirnova, S. E. Severin, R. Uhl, M. Kock, K. D.
A. Aleynik and P. Rameshwar
Geiger, and S. E. Gelperina. Chemotherapy of glioblastoma in rats using
doxorubicin-loaded nanoparticles. Int. J. Cancer. 109 (5): 759–767.
Jones, A. R., and E. V. Shusta. 2007. Blood–Brain Barrier Transport of
Therapeutics via Receptor-Mediation. Pharm. Res. 24 (9): 1759–1771.
Pardridge, W. M. 2001. Brain Drug Targeting and Gene Technologies.
Jpn. J. Pharmacol. 87 (2): 97–103.
Wait, S. D., R. S. Prabhu, S. H. Burri, T. G. Atkins, and A. L. Asher.
Polymeric drug delivery for the treatment of glioblastoma. Neuro-
Oncology 17 (2): ii9–ii23.
Larsen, J.M., D. R. Martin, and M. E. Byrne. 2014. Recent advances
in delivery through the blood–brain barrier. Curr. Top. Med. Chem. 14
(9): 1148–1160.
Jewell, C.M., S. C. Bustamante Lopez, and D. J. Irvine. 2011. In
situ engineering of the lymph node microenvironment via intranodal
injection of adjuvant-releasing polymer particles. PNAS 108 (38):
–15750.
Burgess, A., C.A. Ayala-Grosso, M. Ganguly, J.F. Jordão, I. Aubert, K.
Hynynen. 2011. Targeted Delivery of Neural Stem Cells to the Brain
Using MRI-Guided Focused Ultrasound to Disrupt the Blood–Brain
Barrier. PLoS ONE 6 (11): e27877.
Balyasnikova, I. V., M. S. Prasol, S. D. Ferguson, Y. Han, A. U. Ahmed,
M. Gutova,A. L. Tobias, D. Mustafi, E. Rincon, L. Zhang, K. S.Aboody,
and M. S. Lesniak. 2014. Intranasal delivery of mesenchymal stem cells
significantly extends survival of irradiated mice with experimental brain
tumors. Mol. Ther. 22: 140–148.
Sampson, J. H., K. D. Alpade, G. E. Archer, A. Coan, A. Desjardins,
A. H. Friedman, H. S. Friedman, M. R. Gilbert, J. E. Herndon, R. E.
McLendon, D. A. Mitchell, D. A. Reardon, R. Sawaya, R. Schmittling,
W. Shi, J. J. Vredenburgh, D. D. Bigner, and A. B. Heimberger. 2011.
Greater chemotherapy-induced lymphopenia enhances tumor-specific
immune responses that eliminate EGFRvIII-expressing tumor cells in
patients with glioblastoma. Neuro-Oncology 13 (3): 324–333.
Phuphanich, S., C. J. Wheeler, J. D. Rudnick, M. Mazer, H. Q. Wang,
M. A. Nuno, J. E. Richardson, X. Fan, J. Ji, R.M. Chu, J. G. Bender, E.
S. Hawkins, C. G. Patil, K. L. Black, and J. S. Yu. 2013. Phase I trial
of a multi-epitope-pulsed dendritic cell vaccine for patients with newly
diagnosed glioblastoma. Cancer Immunol. Immunother. 62: 125–135.
Fadul, C. E., J. L. Fisher, T. H. Hampton, E. C. Lallana, Z. Li, J.
Gui, Z. M. Szczepiorkowki, T. D. Tosteson, C. H. Rhodes, H. A.
Stem Cell Therapy for Brain Tumors 105
Wishart, L. D. Lewis, and M. S. Ernstoff. 2011. Immune response
in patients with newly diagnosed glioblastoma multiforme treated
with intranodal autologous tumor lysate-dendritic cell vaccination after
radiation chemotherapy. J. Immunother. 34 (4): 382–389.
Shand, N., F. Weber, L. Mariani, M. Bernstein, A. Gianella-Borradi,
Z. Long, A. G. Sorensen, and N. Barbier. 1999. A phase 1–2 clinical
trial of gene therapy for recurrent glioblastoma multiforme by tumor
transduction with the herpes simplex thymidine kinase gene followed
by ganciclovir. Hum. Gene Ther. 10 (14): 2325–2335.
Markert, J. M., P. G. Liechty, W. Wang, S. Gaston, E. Braz, M. Karrasch,
L. B. Nabors, M. Markiewicz, A. D. Lakeman, C. A. Palmer, J. N.
Parker, R. J. Whitley, G. Y. Gillespie. 2009. Phase Ib trial of mutant
herpes simplex virus G207 inoculated pre-and post-tumor resection for
recurrent GBM. Mol. Ther. 17 (1): 199–207